Overcoming Resistance
People with metastatic hormone receptor-positive breast cancer are living longer, thanks to new targeted therapies and endocrine therapies that can be prescribed when treatment resistance develops.
Progress Against Cancer
People with metastatic hormone receptor-positive breast cancer are living longer, thanks to new targeted therapies and endocrine therapies that can be prescribed when treatment resistance develops.
Blood tests can guide treatment choices, delivering results in less time than traditional biopsies.
The FDA has approved the Immunotherapy durvalumab in combination with chemotherapy for certain patients with resectable bladder cancer. The U.S. Food and Drug Administration (FDA) has approved durvalumab (Imfinzi) in combination with chemotherapy before...
New prostate cancer surgery approach can prevent sexual side effects, and some people with esophageal cancer may be able to avoid surgery.
The FDA has approved the radiotherapy lutetium Lu 177 vipivotide tetraxetan for certain patients with metastatic prostate cancer. The U.S. Food and Drug Administration (FDA) has approved lutetium Lu 177 vipivotide tetraxetan (Pluvicto) for...
This month, the editors of AACR's journals tout studies showcasing the immunostimulatory impact of senescent cancer cells, a novel bispecific immunotherapy, and more.
A promising new personalized vaccine headlines several recent breakthroughs that highlight progress in kidney cancer research.
The FDA has approved the multi-kinase inhibitor cabozantinib for certain adult and pediatric patients with rare neuroendocrine tumors. The U.S. Food and Drug Administration (FDA) has approved cabozantinib (Cabometyx) for patients 12 years and...
Cooling and compression help manage common side effect of chemotherapy, and deadlines encourage people to complete colorectal cancer screening.
After Craig Schumpert learned he had lung cancer that had spread to his brain, bones, and lymph nodes, he started radiation therapy. His oncologist told him he might be eligible for targeted therapy, but...
AACR Fellow Lewis C. Cantley, PhD, leads a national effort targeting triple-negative breast cancer and ovarian cancer with a novel drug combination.
Learn More